Archive for 2007

Aspen and Strides Enter Into Broad and Strategic Partnership

Johannesburg South Africa, and Bangalore, India: Aspen Pharmacare (Aspen), Africa’s largest pharmaceutical manufacturer and the largest generics manufacturer in the southern hemisphere, has entered into a series of transactions with Bangalore-based Strides Arcolab Limited (Strides), one of India’s largest exporters of pharmaceutical products. The transactions comprise: the acquisition by Aspen of 50% of Strides’ Latin…

Read More

Aspen operating profit exceeds R1bn

Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has announced a sound set of results for the financial year ended June 30, 2007. These results take into account the higher effective tax rate of 28,9% (2006:25.3 percent). Revenue increased by 17% to R4,026 billion (R3.449 billion). Operating profit increased by 20% to R1,077…

Read More

Aspen Scientific and Technical capabilities provide strong export growth potential

JSE listed Aspen (APN), Africa and the Southern hemisphere’s largest pharmaceutical manufacturer, has hosted the Honourable Minister Mosibudi Mangena, MP, South African Minister of Science and Technology, at their flagship Port-Elizabeth manufacturing site. The visit was aimed at exploring areas where the Department of Science and Technology (DST) can support local manufacturers in realising greater…

Read More

Key ARV Products Viread® and Truvada® Registered by MCC

JSE listed Aspen, a leading global manufacturer and distributor of anti-retroviral (ARV) medicines, today announced that it has been granted certification from the Medicines Control Council of South Africa (MCC) to manufacture and distribute the two key ARV products Viread® (tenofovir disoproxil fumarate) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) in the South African market.…

Read More

Tibotec and Aspen Collaborate on PREZISTA™ access plan for Africa

Co Cork, Ireland (April 4th, 2007) – Tibotec Pharmaceuticals Ltd. has signed a royalty-free, non-exclusive license agreement with Aspen of South Africa. Aspen will register, package and distribute the protease inhibitor PREZISTA™ (darunavir, DRV) in sub-Saharan Africa. Tibotec has selected Aspen because of the company’s extensive African distribution network and pioneering endeavors in enhancing access…

Read More

Aspen and Strides enter into broad and strategic partnership

Johannesburg South Africa, and Bangalore, India: Aspen Pharmacare (Aspen), Africa’s largest pharmaceutical manufacturer and the largest generics manufacturer in the southern hemisphere, has entered into a series of transactions with Bangalore-based Strides Arcolab Limited (Strides), one of India’s largest exporters of pharmaceutical products. The transactions comprise: the acquisition by Aspen of 50% of Strides’ Latin…

Read More

Aspen records 15% increase in revenue

Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has recorded positive results for the period ended December 2006. Revenue increased by 15 percent to R1,936 billion (R1.687 billion). Net profit after tax rose 15 percent to R332 million (R288.5 million). Earnings per share increased by 13 percent to 95,3 cents (84,5 cents). Headline…

Read More

Appointment of Alternate Director

Aspen has appointed Derek Thomas, BCom (Finance and Economics); BCom (Hons) (Economics); MCOM (Economics); MSc (Economics), as an alternate director to Pasco Dyani with effect from 6 February 2007. Since 2000, Derek has served as CEO of CEPPWAWU Investments (Pty) Ltd, a broad based black economic empowerment investment company (wholly owned by a Trust formed…

Read More

Once-offs results in 235% increase in HEPS

Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has announced impressive results for the financial year ended June 30, 2006. These are the first set of annual results reported under International Financial Reporting Standards (IFRS). Headline earnings per share (HEPS) grew by 235 percent to 185.5 cents (144.7 cents). Revenue increased by 23…

Read More